Details

<p>List of Contributors, viii</p> <p>Foreword, xix</p> <p>Preface, xxi</p> <p><b>Section I: Platelet biology and pathophysiology</b></p> <p>1 Platelet Pathophysiology and its Role in Thrombosis, 3<br /> <i>Paul A. Gurbel and Udaya S. Tantry</i></p> <p>2 Platelet Receptors and Drug Targets: COX-1, 8<br /> <i>Thomas Hohlfeld and Karsten Schror</i></p> <p>3 Platelet Receptors and Drug Targets: P2Y12, 14<br /> <i>Marco Cattaneo</i></p> <p>4 Platelet Receptors and Drug Targets: GP IIb/IIIa, 21<br /> <i>Eliano Pio Navarese and Jacek Kubica</i></p> <p>5 Platelet Receptors and Drug Targets: PAR1, Collagen, vWF, Thromboxane, and Other Novel Targets, 29<br /> <i>Ping Zhang, Lidija Covic, and Athan Kuliopulos</i></p> <p>6 Role of Inflammation and Hypercoagulability in Thrombosis, 45<br /> <i>Paul A. Gurbel, Nachiket Apte, and Udaya S. Tantry</i></p> <p><b>Section II: Platelet function tests</b></p> <p>7 Light Transmission Aggregometry, 53<br /> <i>Paul A. Gurbel, Martin Gesheff, Kevin P. Bliden, and Udaya S. Tantry</i></p> <p>8 Vasodilator-Stimulated Phosphoprotein (VASP) Assay, 58<br /> <i>Marc Laine, Franck Paganelli, and Laurent Bonello</i></p> <p>9 VerifyNow P2Y12 and Plateletworks Assays, 65<br /> <i>Matthew J. Price, Nicoline J. Breet, and Jurriën M. ten Berg</i></p> <p>10 Multiplate Analyzer, 82<br /> <i>Martin Orban and Dirk Sibbing</i></p> <p>11 Shear Stress-Based Platelet Function Tests, 92<br /> <i>Nicoline J. Breet and Jurriën M. ten Berg</i></p> <p>12 Thrombelastography and Other Novel Techniques, 102<br /> <i>Udaya S. Tantry, Vijay A. Doraiswamy, Glenn Stokken, Marvin J. Slepian, and Paul A. Gurbel</i></p> <p><b>Section III: Antiplatelet pharmacology</b></p> <p>13 Aspirin, 111<br /> <i>Karsten Schrör and Thomas Hohlfeld</i></p> <p>14 Cilostazol, 117<br /> <i>Seung-Whan Lee, Duk-Woo Park, and Seung-Jung Park</i></p> <p>15 Abciximab, 125<br /> <i>J. Emilio Exaire and Jorge F. Saucedo</i></p> <p>16 Tirofiban, 131<br /> <i>Marco Valgimigli, Arnoud W.J. van't Hof, and Christian Hamm</i></p> <p>17 Eptifibatide, 142<br /> <i>Nevin C. Baker and Ron Waksman</i></p> <p>18 Ticlopidine, 150<br /> <i>Fabiana Rollini, Francesco Franchi, Ana Muñiz-Lozano, and Dominick J. Angiolillo</i></p> <p>19 Clopidogrel, 160<br /> <i>Andrzej Budaj</i></p> <p>20 Prasugrel, 166<br /> <i>Christoph Varenhorst, Anna Oskarsson, and Stefan James</i></p> <p>21 Elinogrel, 173<br /> <i>Matthew J. Chung and Sunil V. Rao</i></p> <p>22 Cangrelor, 180<br /> <i>Francesco Franchi, Fabiana Rollini, Ana Muñiz-Lozano, and Dominick J. Angiolillo</i></p> <p>23 Ticagrelor, 193<br /> <i>Anna Oskarsson, Christoph Varenhorst, and Stefan James</i></p> <p>24 Thrombin Receptor Antagonists, 198<br /> <i>Flavio de Souza Brito and Pierluigi Tricoci</i></p> <p><b>Section IV: Percutaneous Coronary Intervention and Antiplatelet Therapy</b></p> <p>25 Dual Antiplatelet Therapy Prior to Percutaneous Coronary Intervention, 209<br /> <i>Fabio Mangiacapra, Annunziata Nusca, Rosetta Melfi, and Germano di Sciascio</i></p> <p>26 Duration of Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation, 220<br /> <i>Joshua P. Loh and Ron Waksman</i></p> <p>27 Antiplatelet Therapy for Patients with Acute Coronary Syndromes, 229<br /> <i>Michael A. Gaglia, Jr. and Ray V. Matthews</i></p> <p>28 Antiplatelet Therapy in Stable Coronary Artery Disease, 237<br /> <i>Ana Laynez and Ron Waksman</i></p> <p>29 Antiplatelet Therapy for Patients with Peripheral Arterial Disease, 245<br /> <i>Aung Myat, Yousif Ahmad, and Simon R. Redwood</i></p> <p>30 Bleeding Risk and Outcomes of Patients Undergoing Percutaneous Coronary Intervention Treated with Antiplatelets, 253<br /> <i>Sa'ar Minha and Ron Waksman</i></p> <p>31 Bleeding Definitions, 259<br /> <i>Sameer Bansilal, Deborah E. Aronson, and Roxana Mehran</i></p> <p><b>Section V: Antiplatelet Responsiveness</b></p> <p>32 Personalizing Antiplatelet Therapy, 269<br /> <i>Paul A. Gurbel, Young-Hoon Jeong, and Udaya S. Tantry</i></p> <p>33 Aspirin Resistance, 277<br /> <i>Muthiah Vaduganathan and Eli I. Lev</i></p> <p>34 Clopidogrel Resistance, 285<br /> <i>Udaya S. Tantry, Kevin P. Bliden, Talha Meeran, and Paul A. Gurbel</i></p> <p>35 Genetics of Clopidogrel Poor Response, 293<br /> <i>Pierre Fontana and Jean-Luc Reny</i></p> <p>36 Proton Pump Inhibitors and Clopidogrel, 300<br /> <i>Michael A. Gaglia, Jr</i></p> <p>37 Other Drug Interactions with Clopidogrel, 306<br /> <i>Eric R. Bates</i></p> <p>Index, 314</p>

<p><b>“</b>Written by an international who's-who of experts in the field, Antiplatelet Therapy also includes an entire section covering the use of antiplatelet drugs in PCIs, including percutaneous valve repair, which makes this text particularly essential to Interventional Cardiologists.”  (<i>Kingbook73's Medical Ebook and Video Collection</i>, 20 August 2014)</p>

<p><strong>Ron Waksman</strong>, MD, FACC, is Associate Director, Division of Cardiology and Director of Experimental Angioplasty & New Technologies, Washington Hospital Center, Washington, DC. Dr. Waksman is currently the Editor-in-Chief of <em>Cardiovascular Revascularization Medicine</em> and sits on the editorial boards of six other internationally published journals. He has been Editor/Co-Editor of six books since 1996 and has authored 22 additional book chapters. Dr. Waksman has also authored/co-authored over 250 published manuscripts and over 200 abstracts. He is also a Clinical Professor of Medicine (Cardiology) at Georgetown University, Washington, DC, USA.

<p>Edited by a team of the world’s leading interventional cardiologists and educators, this new book is created with an eye to giving the reader a solid, practical, and clinically focused understanding of this important class of drugs, from basic science to a clear-headed discussion of complex topics such as combination therapies, drug-to-drug interactions, and resistance to antiplatelet agents.</p> <p> </p> <p>This important new book:</p> <ul> <li>Begins with a concise but thorough discussion of platelet biology and pathophysiology so that readers understand how antiplatelet agents work and why they produce such a varied range of complications, from minor GI upset to potentially life-threatening conditions such as neutropenia, a critical shortage of white blood cells.</li> <li>Thoroughly covers platelet function testing, including novel techniques.</li> <li>Clarifies current best practice regarding the use of antiplatelet agents in both chronic and acute cardiovascular disease.</li> <li>Reviews all types of antiplatelet agents – from aspirin to recently approved drugs – including indications, clinical outcomes, and side effects.</li> </ul> <p> </p> <p>Written by an international “who’s who” of experts in the field, <b><i>Antiplatelet Therapy in Cardiovascular Disease</i></b> also includes an entire section covering the use of antiplatelet drugs in PCIs, including percutaneous valve repair, which makes this text particularly essential to interventional cardiologists.</p>

GB